10x Genomics (TXG) Cost of Revenue (2018 - 2026)

10x Genomics has reported Cost of Revenue for 9 years, with the latest figure at $44.7 million in Q1 2026.

• Quarterly Cost of Revenue fell 9.65% year-over-year to $44.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $194.2 million (down 1.76% YoY) and the FY2025 annual result came in at $198.9 million, up 1.34% from the prior year.
• Cost of Revenue fell to $44.7 million in Q1 2026 per TXG's latest filing, from $53.0 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $68.2 million in Q4 2023 and troughed at $25.5 million in Q1 2022.
• A 5-year average of $45.3 million and a median of $47.8 million in 2025 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2022 and 2024: Cost of Revenue surged 463.66% in 2022, then slipped 22.12% in 2024.
• Over 5 years, Cost of Revenue stood at $36.8 million in 2022, then surged by 85.18% to $68.2 million in 2023, then declined by 20.72% to $54.1 million in 2024, then slipped by 2.0% to $53.0 million in 2025, then fell by 15.7% to $44.7 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $44.7 million, $53.0 million, and $48.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.